Mylan has struck a deal to commercialize Lupin's biosimilar Enbrel (etanercept), continuing to seize opportunities beyond existing alliances to ensure an early play in certain key markets. Longstanding Mylan partner Biocon maintains that it won't lose out either, though the outlook for their partnered etanercept is unclear, at least for now.
Mylan NV is leap-frogging plans for biosimilar etanercept in certain key markets via an alliance with Lupin, along the lines of similar efforts for biosimilar adalimumab earlier this year.
The US firm has inked a deal to commercialize Lupin Ltd.’s biosimilar version to Amgen Inc./Pfizer Inc